Lilly requests revoking emergency use for bamlanivimab alone in covid

 - Final step in Lilly's planned transition to provide only bamlanivimab and etesevimab together in the U.S.

- Bamlanivimab and etesevimab together now fully available across the U.S.

- Lilly, in collaboration with Amgen, expects to manufacture sufficient supply for complete global transition by June 2021

https://www.prnewswire.com/news-releases/lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-covid-19-in-the-us-301270317.html